PRMT5 Antibody [M17F9] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat, Monkey

Lane 1: Hela, Lane 2: C2C12, Lane 3: H-4-II-E, Lane 4: Vero

Usage Information

Dilution
WB1:1000 IP1:50 IHC1:400-1:1600

Application
WB, IP, IHC

Reactivity
Human, Mouse, Rat, Monkey

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
73 kDa

Datasheet & SDS

Biological Description

Specificity
PRMT5 Antibody [M17F9] detects endogenous levels of total PRMT5 protein.

Clone
M17F9

Synonym(s)
Protein arginine N-methyltransferase 5; PRMT5; 72 kDa ICln-binding protein; Jak-binding protein 1; Shk1 kinase-binding protein 1 homolog (SKB1 homolog; SKB1Hs); HRMT1L5; IBP72; JBP1; SKB1

Background
PRMT5 (protein arginine methyltransferase 5) is a type II arginine methyltransferase that forms a stable complex with the methyltransferase cofactor WD repeat domain 77 (WDR77/MEP50) and is widely expressed in mammalian cells, where it catalyzes symmetric dimethylation of arginine residues on histones and multiple non‑histone substrates. PRMT5 is incorporated into chromatin remodeling complexes such as SWI/SNF and NuRD and methylates histones H3 and H4, which modulates chromatin compaction and transcriptional repression at specific loci, including genes involved in differentiation and cell‑cycle control. PRMT5 also methylates RNA‑processing factors and transcriptional regulators, thereby influencing pre‑mRNA splicing, export, and the activity of key signaling effectors, and contributes to the regulation of pathways such as p53‑dependent stress responses, translation initiation via eIF4E, and EGFR/Akt/GSK3β signaling in cancer cells. PRMT5 activity is required for G1‑to‑S phase progression, and loss or inhibition of PRMT5 triggers cell‑cycle arrest and reduces expression of cyclins and other growth‑promoting factors, whereas PRMT5 upregulation or aberrant activity is linked to enhanced proliferation and survival in multiple tumors. PRMT5‑dependent methylation modulates interferon and inflammatory signaling in T cells, and PRMT5 inhibition has been shown to blunt interferon‑stimulated gene expression and STAT1 activation, linking it to immune‑cell activation and inflammatory disease.

Background

PRMT5 (protein arginine methyltransferase 5) is a type II arginine methyltransferase that forms a stable complex with the methyltransferase cofactor WD repeat domain 77 (WDR77/MEP50) and is widely expressed in mammalian cells, where it catalyzes symmetric dimethylation of arginine residues on histones and multiple non‑histone substrates. PRMT5 is incorporated into chromatin remodeling complexes such as SWI/SNF and NuRD and methylates histones H3 and H4, which modulates chromatin compaction and transcriptional repression at specific loci, including genes involved in differentiation and cell‑cycle control. PRMT5 also methylates RNA‑processing factors and transcriptional regulators, thereby influencing pre‑mRNA splicing, export, and the activity of key signaling effectors, and contributes to the regulation of pathways such as p53‑dependent stress responses, translation initiation via eIF4E, and EGFR/Akt/GSK3β signaling in cancer cells. PRMT5 activity is required for G1‑to‑S phase progression, and loss or inhibition of PRMT5 triggers cell‑cycle arrest and reduces expression of cyclins and other growth‑promoting factors, whereas PRMT5 upregulation or aberrant activity is linked to enhanced proliferation and survival in multiple tumors. PRMT5‑dependent methylation modulates interferon and inflammatory signaling in T cells, and PRMT5 inhibition has been shown to blunt interferon‑stimulated gene expression and STAT1 activation, linking it to immune‑cell activation and inflammatory disease.

References
https://pubmed.ncbi.nlm.nih.gov/27480244/ https://pubmed.ncbi.nlm.nih.gov/19528079/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%